{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:56:00Z","timestamp":1794362160741,"version":"4.9.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The rarity of lipodystrophies implies that they are not well-known, leading to delays in diagnosis\/misdiagnosis. The aim of this study was to assess the natural course and comorbidities of generalised and partial lipodystrophy in Spain to contribute to their understanding. Thus, a total of 140 patients were evaluated (77.1% with partial lipodystrophy and 22.9% with generalised lipodystrophy). Clinical data were collected in a longitudinal setting with a median follow-up of 4.7 (0.5-17.6) years. Anthropometry and body composition studies were carried out and analytical parameters were also recorded. The estimated prevalence of all lipodystrophies in Spain, excluding K\u00f6bberling syndrome, was 2.78 cases\/million. The onset of phenotype occurred during childhood in generalised lipodystrophy and during adolescence-adulthood in partial lipodystrophy, with the delay in diagnosis being considerable for both cohorts. There are specific clinical findings that should be highlighted as useful features to take into account when making the differential diagnosis of these disorders. Patients with generalised lipodystrophy were found to develop their first metabolic abnormalities sooner and a different lipid profile has also been observed. Mean time to death was 83.8 \u00b1 2.5 years, being shorter among patients with generalised lipodystrophy. These results provide an initial point of comparison for ongoing prospective studies such as the ECLip Registry study.<\/jats:p>","DOI":"10.3389\/fendo.2023.1250203","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:11:05Z","timestamp":1700125865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain"],"prefix":"10.3389","volume":"14","author":[{"given":"Ant\u00eda","family":"Fern\u00e1ndez-Pombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"S\u00e1nchez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Castro-Pais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Ginzo-Villamayor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cobelo-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Prado-Mora\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everardo Josu\u00e9","family":"D\u00edaz-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Loidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ara\u00fajo-Vilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: A multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and treatment of lipodystrophy: a step-by-step approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/db19-0447","article-title":"et al; Geisinger-Regeneron DiscovEHR collaboration","volume":"69","author":"Gonzaga-Jauregui","year":"2020","journal-title":"Clin Mol Prevalence Lipodystrophy an Unascertained Large Clin Care Cohort Diabetes"},{"key":"B5","first-page":"296","article-title":"Burden of illness associated with generalized lipodystrophy in leptin replacement therapy-na\u00efve patients: A longitudinal medical chart review study","volume-title":"54th EASD annual meeting 2018","author":"Akinci","year":"2018"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-1005","article-title":"Natural history of congenital generalized lipodystrophy: A nationwide study from Turkey","volume":"101","author":"Akinci","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Med (Baltimore)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cen.13311","article-title":"Spectrum of disease associated with partial lipodystrophy: lessons from a trial cohort","volume":"86","author":"Ajluni","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2017.04.010","article-title":"Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy","volume":"72","author":"Akinci","year":"2017","journal-title":"Metabolism"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199052","article-title":"Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy","volume":"13","author":"Lima","year":"2018","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14806","article-title":"Describing the natural history of clinical, biochemical and radiological outcomes of children with familial partial lipodystrophy type 2 (FPLD2) from the United Kingdom: A retrospective case series","volume":"97","author":"Zhong","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac155","article-title":"Phenotypic differences among familial partial lipodystrophy due to LMNA or PPARG variants","volume":"6","author":"Vasandani","year":"2022","journal-title":"J Endocr Soc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1002-x","article-title":"Type 1 familial partial lipodystrophy: understanding the K\u00f6bberling syndrome","volume":"54","author":"Guill\u00edn-Amarelle","year":"2016","journal-title":"Endocrine"},{"key":"B15","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume-title":"Diabetes care","year":"2022"},{"key":"B16","article-title":"12. Retinopathy, neuropathy, and foot care: standards of medical care in diabetes-2022","volume-title":"Diabetes care","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0178","article-title":"Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline","volume":"91","author":"Azziz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-016-0684-7","article-title":"The relevance of \u2018mixed anxiety and depression\u2019 as a diagnostic category in clinical practice","volume":"266","author":"M\u00f6ller","year":"2016","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2013-101525","article-title":"A new seipin-associated neurodegenerative syndrome","volume":"50","author":"Guill\u00e9n-Navarro","year":"2013","journal-title":"J Med Genet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2271","article-title":"Clinical features and management of non-HIV-related lipodystrophy in children: A systematic review","volume":"102","author":"Gupta","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"B22","article-title":"Practical guidelines for the diagnosis and treatment of infrequent lipodystrophies","author":"Ara\u00fajo-Vilar","year":"2020","journal-title":"Murcia: AELIP"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.5.6605","article-title":"Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety)","volume":"85","author":"Garg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2012.0214","article-title":"High prevalence and impact on the quality of life of facial lipoatrophy and other abnormalities in fat tissue distribution in HIV-infected patients treated with antiretroviral therapy","volume":"29","author":"Leclercq","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-019-00716-6","article-title":"Psychopathological and psychiatric evaluation of patients affected by lipodystrophy","volume":"25","author":"Calabr\u00f2","year":"2020","journal-title":"Eat Weight Disord"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.01.068","article-title":"The epidemiology of pancreatitis and pancreatic cancer","volume":"144","author":"Yadav","year":"2013","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4510-5","article-title":"Epidemiology of recurrent acute and chronic pancreatitis: similarities and differences","volume":"62","author":"Machicado","year":"2017","journal-title":"Dig Dis Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14800","article-title":"Coronary arterial calcification in patients with congenital generalised lipodystrophy: A case series","volume":"97","author":"Feij\u00f3","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001631","article-title":"Lamin A\/C-related cardiac disease: late onset with a variable and mild phenotype in a large cohort of patients with the lamin A\/C p.(Arg331Gln) founder mutation","volume":"10","author":"Hoorntje","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.12.021","article-title":"Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A","volume":"169","author":"Andre","year":"2015","journal-title":"Am Heart J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.103.18.2225","article-title":"Premature atherosclerosis associated with monogenic insulin resistance","volume":"103","author":"Hegele","year":"2001","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0282","article-title":"A recurrent familial partial lipodystrophy due to a monoallelic or biallelic LMNA founder variant highlights the multifaceted cardiac manifestations of metabolic laminopathies","volume":"185","author":"Treiber","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.113.301933","article-title":"Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction","volume":"33","author":"Bidault","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.09.006","article-title":"Diamenord\u2013AEDNL Working Group. Cardiometabolic assessment of lamin A\/C gene mutation carriers: a phenotype-genotype correlation","volume":"45","author":"Kwapich","year":"2019","journal-title":"Diabetes Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e9349","DOI":"10.7759\/cureus.9349","article-title":"Global epidemiology of ischemic heart disease: results from the global burden of disease study","volume":"12","author":"Khan","year":"2020","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14426","article-title":"Cardiac phenotype in familial partial lipodystrophy","volume":"94","author":"Eldin","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030765","article-title":"Looking at new unexpected disease targets in LMNA-linked lipodystrophies in the light of complex cardiovascular phenotypes: implications for clinical practice","volume":"9","author":"Mosbah","year":"2020","journal-title":"Cells"},{"key":"B43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.metabol.2019.05.001","article-title":"Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and\/or leptin replacement","volume":"96","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4158\/endp.19.1.v767575m65p5mr06","article-title":"American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy - an AACE consensus statement","volume":"19","author":"Handelsman","year":"2013","journal-title":"Endocr Pract"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-200303000-00007","article-title":"Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature","volume":"82","author":"Misra","year":"2003","journal-title":"Med (Baltimore)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5152\/tjg.2020.19114","article-title":"Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy","volume":"31","author":"Altay","year":"2020","journal-title":"Turk J Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/srep18495","article-title":"Associations of different adipose tissue depots with insulin resistance: A systematic review and meta-analysis of observational studies","volume":"5","author":"Zhang","year":"2015","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrendo.2014.185","article-title":"Biology of upper-body and lower-body adipose tissue\u2013link to whole-body phenotypes","volume":"11","author":"Karpe","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129190","article-title":"What lipodystrophies teach us about the metabolic syndrome","volume":"129","author":"Mann","year":"2019","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab216","article-title":"Effect of leptin therapy on survival in generalized and partial lipodystrophy: A matched cohort analysis","volume":"106","author":"Cook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10048-019-00574-5","article-title":"Celia\u2019s encephalopathy and c.974dupG in BSCL2 gene: a hidden change in a known variant","volume":"20","author":"S\u00e1nchez-Iglesias","year":"2019","journal-title":"Neurogenetics"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.39.10.722","article-title":"Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy","volume":"39","author":"Van Maldergem","year":"2002","journal-title":"J Med Genet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.02.003","article-title":"Congenital generalized lipodystrophy in Taiwan","volume":"118","author":"Hsu","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1651-2227.1996.tb14262.x","article-title":"Generalized lipodystrophy, congenital and acquired (lipoatrophy)","volume":"413","author":"Seip","year":"1996","journal-title":"Acta Paediatr Suppl"},{"key":"B56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13023-020-1295-y","article-title":"European lipodystrophy registry: background and structure","volume":"15","author":"von Schnurbein","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-023-02714-5","article-title":"MEASuRE group. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges","volume":"18","author":"Haymond","year":"2023","journal-title":"Orphanet J Rare Dis"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1250203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T09:11:16Z","timestamp":1700125876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1250203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":57,"alternative-id":["10.3389\/fendo.2023.1250203"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1250203","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fendo.2023.1250203.s001","asserted-by":"subject"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1250203"}}